Through comprehensive assessments, ongoing monitoring, and compassionate care, our team supports patients with clear, evidence-based recommendations designed to promote safety, sustainability, and long-term wellness
264 The cardiovascular outcome trial for tirzepatide (SURPASS-CVOT) has demonstrated cardiovascular benefit in people with type 2 diabetes and atherosclerotic CVD
With the next frontier of these blockbuster therapeutics well on its way to approval, the GLP-1 field is only going to grow, with novel combinations, indications, and formulations being explored
However, denials can happen
Gaelikines GLP-1 Modulation Supplement offers a viable path to enhance your wellness plan
Study explains how red meat raises heart disease risk